This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/moderna-stock-price-outlook-covid-220ab37e

Moderna’s Covid Boom Is Ending. Why the Outlook Isn’t All Grim.

By
Josh Nathan-Kazis
  • Order Reprints
  • Print Article

Last week was a bad one for Moderna shareholders.

The biotech company’s shares tumbled 6.7% on Thursday, and another 5.6% on Friday, after its earnings report gave investors a glimpse into how it expects its post-pandemic financials to look.

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.